118 related articles for article (PubMed ID: 2771992)
1. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
Jakse G
Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
[TBL] [Abstract][Full Text] [Related]
2. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors].
Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855
[TBL] [Abstract][Full Text] [Related]
3. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
[TBL] [Abstract][Full Text] [Related]
4. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
5. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
[No Abstract] [Full Text] [Related]
6. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
7. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
8. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
9. [Lower toxicity with the topical low-dose BCG therapy of superficial bladder carcinoma?].
Mack D; Frick J
Urologe A; 1992 Mar; 31(2):88-90. PubMed ID: 1561732
[TBL] [Abstract][Full Text] [Related]
10. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
12. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
[TBL] [Abstract][Full Text] [Related]
13. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder.
Koga H; Kuroda M; Kudo S; Yamaguchi A; Usami M; Suzuki T; Naito S
Int J Urol; 2005 Feb; 12(2):145-51. PubMed ID: 15733108
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical BCG vaccine in bladder cancer].
Beisland HO; Sander S
Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
[TBL] [Abstract][Full Text] [Related]
15. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
16. [Topical BCG therapy of in situ cancer of the urinary bladder].
Mack D; Jakse G
Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
[TBL] [Abstract][Full Text] [Related]
17. [Intravesical Bacillus Calmette Guerin treatment of bladder tumors and carcinoma in situ].
Ovesen H
Ugeskr Laeger; 1994 Jan; 156(5):628-31, 634. PubMed ID: 8184493
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical instillations of BCG and bladder carcinoma in situ].
Haab F; Dauge MC; Delmas V; Boccon-Gibod L
Prog Urol; 1993 Dec; 3(6):988-94; discussion 992-3. PubMed ID: 8305942
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
Ackermann D; Schnyder M; Bandelier D; Studer UE
J Urol (Paris); 1986; 92(1):33-8. PubMed ID: 3722851
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
